Antiviral Drugs - Burundi

Burundi

The projected revenue in the Antiviral Drugs market in Burundi is expected to reach US$0.71m by 2024.
It is anticipated that there will be an annual growth rate of 2.92% between 2024 and 2029, leading to a market volume of US$0.82m by 2029.
When compared globally, United States is expected to generate the highest revenue, with US$30,640.00m in 2024.
Burundi's market for antiviral drugs is experiencing a surge due to the high prevalence of infectious diseases in the country.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Burundi has been experiencing steady growth in recent years.

Customer preferences: The demand for antiviral drugs in Burundi has been increasing due to the rise of infectious diseases in the country. The population has become more aware of the importance of preventive measures and medication to combat these diseases.

Trends in the market: The government of Burundi has been taking steps to improve the healthcare system in the country, which has led to an increase in the availability of antiviral drugs. The market has also been growing due to the expansion of the pharmaceutical industry in the region.

Local special circumstances: Burundi is a landlocked country in East Africa with a population of approximately 12 million people. The country has a high prevalence of infectious diseases such as malaria, tuberculosis, and HIV/AIDS, which has led to an increase in demand for antiviral drugs.

Underlying macroeconomic factors: The Burundian economy has been growing steadily in recent years, with a GDP growth rate of 3.9% in 2019. However, the country still faces challenges such as political instability, poverty, and a weak healthcare system. These factors have contributed to the high prevalence of infectious diseases in the country and the demand for antiviral drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.